AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biotech stocks pharmaceutical company has announced that it has administered the first dose in the Phase 1/2 AVEO-sponsored TiNivo trial whuch is studying tivozanib combined with Opdivo® (nivoluma, a Bristol-Myers Squibb’s anti-PD-1 therapy in advanced stage renal cell carcinoma (RCC).
The clinical study which will be spearheaded by the Institut Gustave Roussy located in Paris is being directed by Professor Bernard Escudier, the Managing Director and Chairman of the Genitourinary Oncology Committee. The first phase of the study will examine the safety of tivozanib combined with nivolumab when administered in high doses of tivozanib. In case the study produces favourable results, it will be allowed to proceed to Phase 2.
Professor Escudier says a combination of antiangiogenic activity of VEGF inhibition and immunologic activity of PD-1 inhibitors have scientifically been proved to produce beneficial results. Low levels of tolerability has however limited advances in the field. He adds that Tivozanib has been established to be the most selective VEGF inhibitor and offers unique favorable tolerability ability.
Tivozanib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and orally administered once a day. The drug is a designed to optimize on the VEGF blockade while at the same time reducing possible off-target toxicities. This potentially results in improved efficacy as well as less modifications in the dosage. The drug has been examined in a number of tumors types including colorectal, renal cell and breast cancers.
AVEO Oncology (AVEO) is a top biotech stocks and biopharmaceutical company mainly engaged in advancing a wide portfolio of potential therapeutics for oncology as well as other areas of unmet medical demand. AVEO Oncology is mainly focused on developing, marketing and commercializing its candidate tivozanib. The company is counting on several partnerships and collaborations to develop market and commercialize the drug in non-oncologic ndications globally as well as oncology indications outside North America. The company also intends to advance its novel therapeutic candidates used in treatment of cancer and cachexia which are still in the pipeline